scholarly journals Safety and efficacy of percutaneous device closure of large post tricuspid shunts in pediatric patients with severe PAH at short term and midterm follow up

2016 ◽  
Vol 4 (10) ◽  
pp. 1724-1730
Author(s):  
Dr Jayal H. Shah ◽  
◽  
Dr Bhavesh M. Thakkar ◽  
Keyword(s):  
Pediatric Patients ◽  
Device Closure ◽  
Short Term ◽  
Safety And Efficacy ◽  
Percutaneous Device ◽  
Percutaneous Device Closure

scholarly journals Percutaneous device closure of patent ductus arteriosus in adult patients with 10-year follow-up

Heart Views ◽  
2019 ◽  
Vol 20 (4) ◽  
pp. 139
Author(s):  
Wail Alkashkari ◽  
Saad Albugami ◽  
Jamilah Alrahimi ◽  
Mohammed Althobaiti ◽  
Abdulhalim Kinsara ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Adult Patients ◽  
Device Closure ◽  
Percutaneous Device ◽  
Percutaneous Device Closure ◽  
Patent Ductus

scholarly journals Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US

Neurology ◽  
2018 ◽  
Vol 91 (19) ◽  
pp. e1778-e1787 ◽  
Author(s):  
Kristen M. Krysko ◽  
Jennifer Graves ◽  
Mary Rensel ◽  
Bianca Weinstock-Guttman ◽  
Gregory Aaen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effect ◽  
Pediatric Patients ◽  
Dimethyl Fumarate ◽  
Short Term ◽  
Pediatric Multiple Sclerosis ◽  
Disease Modifying Therapies ◽  
The Us ◽  
Disease Modifying

ObjectiveTo characterize the use and safety of newer disease-modifying therapies (DMTs) in children with multiple sclerosis (MS) and clinically isolated syndrome (CIS) treated under 18 years of age.MethodsThis is a cohort study including children with MS or CIS followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. Newer DMTs were defined as agents receiving Food and Drug Administration approval or with increased use in adult MS after 2005.ResultsAs of July 2017, 1,019 pediatric patients with MS (n = 748) or CIS (n = 271) were enrolled (65% female, mean onset 13.0 ± 3.9 years, mean follow-up 3.5 ± 3.1 years, median 1.6 visits per year). Of these, 78% (n = 587) with MS and 11% (n = 31) with CIS received DMT before 18 years of age. This consisted of at least one newer DMT in 42%, including dimethyl fumarate (n = 102), natalizumab (n = 101), rituximab (n = 57), fingolimod (n = 37), daclizumab (n = 5), and teriflunomide (n = 3). Among 17%, the initial DMT prescribed was a newer agent (36 dimethyl fumarate, 30 natalizumab, 22 rituximab, 14 fingolimod, 2 teriflunomide). Over the last 10 years, the use of newer agents has increased, particularly in those ≥12 years and to lesser extent in those <12 years. The short-term side effect profiles of newer DMTs did not differ from those reported in adults.ConclusionNewer DMTs are often used in pediatric MS, and have similar short-term safety, tolerability, and side effect profiles as in adults. These findings may help inform pediatric MS management.

Percutaneous device closure of abernethy malformation-A treatable cause of hepatopulmonary syndrome

2013 ◽  
Vol 83 (6) ◽  
pp. 968-970 ◽  
Author(s):  
Subramanian Venkateshwaran ◽  
Kavassery Mahadevan Krishnamoorthy ◽  
Sivasubramonian Sivasankaran
Keyword(s):  
Hepatopulmonary Syndrome ◽  
Device Closure ◽  
Abernethy Malformation ◽  
Percutaneous Device ◽  
Percutaneous Device Closure
Sign in / Sign up

Export Citation Format

Share Document